Microbix Secures Funded Drug Commercialization Agreement
By Microbix Admin | May 16, 2023
Microbix Reports Results for Q2 Fiscal 2023
By Microbix Admin | May 11, 2023
Episode 3: Diagnostics: Beyond the lab – Self-Collection with Copan Italia
By Microbix Admin | April 25, 2023
Diagnostics Beyond the Lab: Ensuring Patient Health through EQA
By Microbix Admin | April 24, 2023
Diagnostics Explained: AMR
By Microbix Admin | February 21, 2023
CEM Muskoka – September 23-25
By Microbix Admin | February 8, 2023
Upcoming Events 2023
By Microbix Admin | February 2, 2023
Upcoming Events: Coming Soon
By Microbix Admin | January 27, 2023
Blog: Episode 3
By Microbix Admin | January 13, 2023
Blog: Episode 2
By Microbix Admin | January 10, 2023
Blog: Episode 1
By Microbix Admin | January 5, 2023
2022 Q2 Financial Report
By Microbix Admin | November 11, 2022
High-Risk HPV Quality Controls are Needed to Uphold Clinical Laboratory Quality Standards
By Microbix Admin | November 10, 2022
Respiratory virus multiplex formulations desiccated on Copan’s FLOQSwab© for use as cross-platform compatible EQA samples and laboratory Quality Control
By Microbix Admin | November 10, 2022
Emerging requirements for infectious disease IVD quality control material
By Microbix Admin | November 10, 2022
Cross-Platform High-Risk (hr) Low Occurrence HPV NAAT Positive Samples of Use in Nucleic Acid Detection Testing as Prospective External Quality Assessment Samples and User Defined Quality Controls
By Microbix Admin | November 10, 2022
Expected stability of REDx™FLOQ © SARS-CoV-2 Swab Positive Control and REDx™FLOQ© SARS-CoV-2 Swab Negative Control in various sample transport media and storage conditions
By Microbix Admin | November 9, 2022
2022 Q3 Financial Report
By Microbix Admin | November 9, 2022
Use of REDx™FLOQ © SARS-CoV-2 Ag Swab Positive Control and REDx™FLOQ© Respiratory Swab Negative Control as Quality Control by POC devices in various testing conditions
By Microbix Admin | November 8, 2022
Novel Cross-Platform High-Risk (hr) HPV NAAT Positive Controls for Use in L1 and E6/E7 Targeted Nucleic ACID (DNA and RNA) Detection Methods
By Microbix Admin | November 8, 2022
Performance of full and extended genotyping assays using a new high-risk HPV multiplex panel
By Microbix Admin | November 7, 2022
Respiratory virus multiplex formulations desiccated on Copan’s FLOQSwab® for use as cross-platform compatible EQA samples and laboratory Quality Control
By Microbix Admin | November 6, 2022
Novel Mycoplasma genitalium (Mgen) and AMR Mgen A2059G Materials for use in a Cross-Platform NAAT Quality Control
By Microbix Admin | November 6, 2022
Simulated swab specimens for whole workflow quality control of SARS-CoV-2 molecular diagnostic testing
By Microbix Admin | November 5, 2022
2022 Q1 Financial Report
By Microbix Admin | November 5, 2022
Advanced SARS-CoV-2 Variants of Concern (VOC) whole-genome materials for use as verification, external quality assessment (EQA) and prospective quality control samples
By Microbix Admin | November 4, 2022
Episode 2: Diagnostics: Beyond the Lab – AMR MGEN with Colin Denver from SpeeDx
By Microbix Admin | November 4, 2022
Advanced SARS-CoV-2 nucleocapsid protein swab-based formulation for use as a cross-platform EQA sample and as a prospective Quality Control
By Microbix Admin | November 3, 2022
Novel neutralizing anti-S1 SARS-CoV-2 human monoclonal antibody formulation for use as a cross-platform EQA sample and prospective quality controls
By Microbix Admin | November 2, 2022
Novel SARS-CoV-2 Full-Genome Material for Use in a Swab-Based Formulation as a Multi-Platform NAAT Quality Control
By Microbix Admin | November 1, 2022
Episode 1: Diagnostics: Beyond the lab – HPV with Larry Vaughn, BD and Dr. Cathy Popadiuk
By Microbix Admin | November 1, 2022
MBX Investor Update Webinar
By Microbix Admin | October 31, 2022
AGM Presentation – March 2022
By Microbix Admin | October 31, 2022
AGM PRESENTATION 2022
By Microbix Admin | October 31, 2022
Microbix Corporate Presentation – September 2022
By Microbix Admin | October 31, 2022
Microbix Corporate Presentation – October 2022
By Microbix Admin | October 31, 2022
Novel Cross-Platform High-Risk (hr) HPV NAAT Positive Controls for Use in L1 and E6/E7 Targeted Nucleic ACID (DNA and RNA) Detection Methods
By Microbix Admin | October 24, 2022
Cross-Platform High-Risk (hr) Low Occurrence HPV NAAT Positive Samples of Use in Nucleic Acid Detection Testing as Prospective External Quality Assessment Samples and User Defined Quality Controls
By Microbix Admin | October 24, 2022
Emerging requirements for infectious disease IVD quality control material
By Microbix Admin | October 18, 2022
CEM Florida – November 11-13
By Microbix Admin | July 25, 2022
About us
By Microbix Admin | June 22, 2022
2022 AMMI Canada-CACMID Annual Conference – April 5-8
By Microbix Admin | March 3, 2022
2022 EUROGIN International Multidisciplinary HPV Congress – April 10-13
By Microbix Admin | March 3, 2022
Why We Need To Test COVID-19 Tests
By Microbix Admin | March 3, 2021
Microbix Discloses New Products, Sales, And Capacity
By Microbix Admin | October 29, 2020
Microbix Creates Further COVID-19 Quality Assessment Products
By Microbix Admin | October 20, 2020
Ontario Helps Microbix Ensure Provincial COVID Testing Capacity
By Microbix Admin | October 13, 2020
Microbix Presenting COVID-19 Product Results To Industry
By Microbix Admin | September 22, 2020
Microbix Announces Extension Of Warrant Expiry Dates
By Microbix Admin | September 17, 2020
Microbix Announces Board Changes
By Microbix Admin | September 15, 2020
Microbix’s REDx™ Controls Attain Australian TGA Registration
By Microbix Admin | September 10, 2020
Q3 Fiscal 2020
By Microbix Admin | August 14, 2020
Curious To See How We Perform A COVID Test?
By Microbix Admin | July 21, 2020
Microbix Shares Become Available For U.S. Investors
By Microbix Admin | July 14, 2020
Microbix COVID-19 QAPs Attain EU “CE Mark” Registration
By Microbix Admin | June 5, 2020
Microbix Announces Quality Products Distribution Agreement
By Microbix Admin | June 4, 2020
Microbix Engaged To Develop & Supply Custom QAPs™
By Microbix Admin | June 2, 2020
Microbix Expanding QAPs™ Production Capacity
By Microbix Admin | May 27, 2020
Microbix Achieves Full Utilization Of Its Bioreactors
By Microbix Admin | May 19, 2020
Microbix Announces Quality Products Distribution Agreement
By Microbix Admin | May 15, 2020
Microbix Reports Record Second Quarter Sales
By Microbix Admin | May 14, 2020
Microbix Reports Results For Q2 Fiscal 2020
By Microbix Admin | May 14, 2020
Microbix Announces Quality Products Distribution Agreement
By Microbix Admin | May 12, 2020
Microbix COVID-19 QAPs Now Available for U.S. Labs
By Microbix Admin | May 7, 2020
Microbix Begins Providing COVID-19 Test Quality Products
By Microbix Admin | May 6, 2020
Microbix Announces Quality Products Distribution Agreement
By Microbix Admin | April 27, 2020
Microbix Participating In COVID-19 Virtual Conference
By Microbix Admin | April 21, 2020
Microbix Attains Health Canada Establishment Licensing
By Microbix Admin | April 21, 2020
How Microbix Core Competency Leads To COVID-19 Products
By Microbix Admin | April 14, 2020
Understanding COVID-19 Mortality Rates
By Microbix Admin | April 13, 2020
Microbix & Oneworld Create COVID-19 Test Quality Program
By Microbix Admin | April 9, 2020
Microbix Announces Annual And Special Meeting Voting Results
By Microbix Admin | April 1, 2020
Microbix Creates Quality Assessment Product For COVID-19 Tests
By Microbix Admin | March 30, 2020
Microbix Annual General Meeting Process Update
By Microbix Admin | March 25, 2020
Microbix Announces Quality Products Distribution Agreement
By Microbix Admin | March 24, 2020
Microbix Announces Issuance Of Stock Options
By Microbix Admin | February 25, 2020
Microbix Reports Results For Q1 Fiscal 2020
By Microbix Admin | February 13, 2020
Annual General Meeting (AGM) – March 31st, 2020 UPDATE!
By Microbix Admin | February 3, 2020
Microbix Completes Non-Brokered Private Placement Of $2.3 Million
By Microbix Admin | January 31, 2020
Microbix Reports Results For Fiscal 2019
By Microbix Admin | December 20, 2019
EUROGIN 2019
By Microbix Admin | December 4, 2019
Microbix Invited To Present Product Results At HPV Congress
By Microbix Admin | December 2, 2019
Microbix Wins Ontario Business Award
By Microbix Admin | November 18, 2019
Microbix Presenting Product Results At Industry Conference
By Microbix Admin | October 8, 2019
Microbix Presenting At StableView TECH19 Conference
By Microbix Admin | October 1, 2019
Microbix Presenting At Muskoka Capital Conference
By Microbix Admin | September 25, 2019
Microbix Quality Products Enter U.S. Market
By Microbix Admin | September 19, 2019
Microbix Quality Products Attain European Registration
By Microbix Admin | September 5, 2019
Microbix Reports Results For Q3 Fiscal 2019
By Microbix Admin | August 12, 2019
Microbix Provides Bioreactor Update
By Microbix Admin | August 1, 2019
FedDev Ontario Supports New Microbix Facility In Mississauga
By Microbix Admin | July 30, 2019
EMMD 11th Edition
By Microbix Admin | July 9, 2019
Microbix Reports Results For Q2 Fiscal 2019
By Microbix Admin | May 13, 2019
Microbix Will Be Exhibiting At The 35th Annual ASM Clinical Virology Symposium
By Microbix Admin | May 4, 2019
Microbix To Present At Bloom Burton Conference
By Microbix Admin | April 29, 2019
Microbix Announces Management Changes
By Microbix Admin | April 18, 2019
Microbix Announces Annual Meeting Voting Results
By Microbix Admin | March 28, 2019
Microbix Will Be Exhibiting At The 29th Annual ECCMID
By Microbix Admin | March 18, 2019
Annual General Meeting (AGM) – March 27th, 2019
By Microbix Admin | March 5, 2019
Microbix Announces Issuance Of Stock Options
By Microbix Admin | February 25, 2019
customer.service@microbix.com 
+1-905-361-8910 +1-800-794-6694 (Toll Free)
